Afuresertib hydrochloride is primarily used in the field of oncology as a potent and selective inhibitor of the AKT pathway, which plays a critical role in cell survival and proliferation. It is being investigated for its potential to treat various cancers, particularly those that are resistant to conventional therapies. The compound is often studied in clinical trials for its effectiveness in targeting cancers such as breast, ovarian, gastric, and prostate cancers, where the AKT pathway is frequently dysregulated. By inhibiting this pathway, it aims to halt tumor growth and improve patient outcomes. Additionally, its use in combination with other anticancer agents is being explored to enhance therapeutic efficacy and overcome drug resistance.